Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database
Drug Safety · 2025
DOI: 10.1007/s40264-025-01535-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Safety, 2025. Verfasst von Raffaella Di Napoli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Department of Experimental Medicine, Section of Pharmacology "L. Donatelli",…. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Cardiovascular Diseases, Antirheumatic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Università degli Studi della Campania Luigi Vanvitelli.
Abstract (Originalsprache)
BACKGROUND: Rheumatoid arthritis (RA) is commonly treated with Janus kinase inhibitors (JAKis) and anti-tumor necrosis factor-α (anti-TNFα), but the cardiovascular safety profiles of these drugs remain unclear. OBJECTIVE: The aim of this study was to describe the individual case safety reports of major adverse cardiac events (MACE) or stroke and to determine whether there was a difference in the frequency of reporting of cardiovascular events between JAKis and anti-TNFα used in RA. METHODS: A case/non-case study was conducted using the WHO VigiBase® database. Descriptive analysis was performed, the time to onset (TTO) of MACE was calculated, and the reporting odds ratio (ROR) was used to estimate the frequency of MACE reports associated with JAKis versus anti-TNFα in RA. RESULTS: A total of 18,099 cases of MACE were identified, of which 2543 (14%) were associated with JAKis, predominantly in women (65.4%) and in patients aged ≥65 years (49.9%). The median time to onset was 210 days (IQR 60-510) for JAKis and 690 days (210-1460) for anti-TNFα. JAKis were associated with higher odds of reporting MACE (ROR 1.38 [95% CI 1.32-1.44]), mainly due to non-fatal stroke (1.65 [1.55-1.75]). Stroke as a whole showed similar results (1.62 [1.53-1.72]). The ROR of MACE was also slightly increased in patients aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Department of Experimental Medicine, Section of Pharmacology "L. Donatelli", University of Campania "Luigi Vanvitelli", Via Costantinopoli 16, 801…
- Department of Experimental Medicine-Section of Pharmacology "L. Donatelli", University of Campania "Luigi Vanvitelli", Naples, Italy. raffaella.dinapoli@unicampania.it.
- Université de Bordeaux, INSERM, Bordeaux Population Health, U1219, AHeaD Team, 33000, Bordeaux, France. raffaella.dinapoli@unicampania.it.
- Service de Rhumatologie, Centre de référence des maladies auto-immunes systémiques rares RESO, Hôpital Pellegrin, Centre Hospitalier Universitaire, Bordeaux, France.
- CNRS-UMR 5164, ImmunoConcept, Université de Bordeaux, Bordeaux, France.
- Department of Experimental Medicine-Section of Pharmacology "L. Donatelli", University of Campania "Luigi Vanvitelli", Naples, Italy.
Förderung
- Università degli Studi della Campania Luigi Vanvitelli
Zitieren
APA
Di Napoli, R., Richez, C., Scavone, C., Singier, A., Demourgues, M., Mascolo, A., Capuano, A., & Salvo, F. (2025). Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database. Drug Safety. https://doi.org/10.1007/s40264-025-01535-8
Vancouver
Di Napoli R, Richez C, Scavone C, Singier A, Demourgues M, Mascolo A, et al. Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database. Drug Safety. 2025. doi:10.1007/s40264-025-01535-8
BibTeX
@article{DiNapoli2025,
author = {Di Napoli, Raffaella and Richez, Christophe and Scavone, Cristina and Singier, Allison and Demourgues, Maxime and Mascolo, Annamaria and Capuano, Annalisa and Salvo, Francesco},
title = {Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database},
journal = {Drug Safety},
year = {2025},
doi = {10.1007/s40264-025-01535-8}
}
EUVIMED